Respirology Case Reports OPEN CACCESS



Acute saddle pulmonary embolism on ¹⁸F-FDG PET/CT: diagnosis by functional imaging

Dalveer Singh^{1,2}, Roslyn Foessel¹, Navjot Nagra¹, Pauline Lau¹ & Damian Brauchli¹

¹Department of Nuclear Medicine, Qscan Radiology Clinics, Brisbane, Australia. ²School of Medicine, University of Queensland, Brisbane, Australia.

Keywords

Abstract

Positron emission tomography/computed tomography, pulmonary embolus, right heart strain, rim sign.

Correspondence

Dalveer Singh, Department of Nuclear Medicine, Qscan Radiology Clinics, College Junction 2-12 Wagner Road, Clayfield, Queensland 4011, Australia. E-mail: dalveer.singh@qscan.com.au

Received: 6 July 2019; Revised: 24 July 2019; Accepted: 26 July 2019; Associate Editor: James Ho.

Respirology Case Reports, 7 (8), 2019, e00476

doi: 10.1002/rcr2.476

¹⁸F-labelled fluoro-2-deoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is used extensively in the setting of cancer staging and in assessing cancer treatment response. Oncology patients have a sevenfold risk of developing pulmonary embolism (PE) due to underlying activation of the haemostatic system and anti-cancer therapy inducing a hypercoagulable state. The diagnosis of PE on ¹⁸F-FDG PET/CT is challenging, particularly in the absence of intravenous contrast. The case of a female patient undergoing treatment for advanced diffuse large B-cell lymphoma is presented. The ancillary signs of PE are illustrated on consecutive non-contrast-enhanced ¹⁸F-FDG PET/CT scans. The signs include the "rim sign" relating to regions of pulmonary infarction and abnormal cardiac uptake indicating right heart strain. The diagnosis was confirmed on CT pulmonary angiography which demonstrated extensive PE, including a saddle embolus.

Introduction

Pulmonary embolism (PE) is the second leading cause of death in patients with cancer [1]. Overall, the risk of PE is sevenfold in oncology patients compared with the general population [2], which is attributable to inherent cancermediated mechanisms and anti-cancer therapies inducing a hypercoagulable state. Cancers that are at particularly high risk are haematological, lung, and gastrointestinal (28-fold, 22-fold, and 20-fold risk, respectively). Coincidentally, ¹⁸F-labelled fluoro-2-deoxyglucose positron emistomography/computed tomography (¹⁸F-FDG sion PET/CT) is an extremely useful tool in this subset of cancers and is performed in the majority of patients for staging and to assess treatment response. In the setting of non-contrast-enhanced ¹⁸F-FDG PET/CT, it is important to recognize the indirect signs of PE so that patients can be appropriately treated. We present a case illustrating typical non-contrast-enhanced ¹⁸F-FDG PET/CT findings of PE in a patient undergoing treatment for diffuse large B cell lymphoma (DLBCL).

Case Report

A middle-aged female presented for a non-contrast ¹⁸F-FDG PET/CT scan for restaging of advanced DLBCL post completion of R-CHOP (rituximab cyclophosphamide doxorubicin) chemotherapy. She had known widespread nodal and extra-nodal disease (including brain), and documented episodes of acute tachycardia and dyspnoea seven weeks earlier. The non-contrast CT images demonstrated a peripheral area of ground glass with surrounding consolidation in the posterior right lower lobe. The PET data confirmed a corresponding rim of low-level ¹⁸F-FDG uptake with central photopaenia, consistent with the "rim sign" (Fig. 1).

Four weeks later while the patient was undergoing whole brain radiation for residual intracranial DLBCL, the patient returned for an ¹⁸F-FDG PET/CT surveillance scan. Peripheral ground glass with a rim of low-level ¹⁸F-FDG uptake was again demonstrated, this time within the left lower lobe (Fig. 2) with the additional finding of four-chamber cardiac ¹⁸F-FDG uptake.

© 2019 The Authors. *Respirology Case Reports* published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology

2019 | Vol. 7 | Iss. 8 | e00476 Page 1

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.



Figure 1. Right lower lobe opacity demonstrating the "rim sign" (arrow).

The patient deteriorated with acute tachycardia, dyspnoea, and left pleuritic chest pain three hours after the scan. A CT pulmonary angiography (CTPA) was performed, diagnosing extensive lobar, segmental, subsegmental, and saddle PE. There were no features of right heart strain (RHS) on the CTPA.

After four weeks of oral anticoagulants and completion of the rapy for DLBCL, a follow-up $^{18}\mbox{F-FDG}$ PET/CT scan



Figure 2. Left lower lobe "rim sign" (short arrow) and four-chamber cardiac uptake (best appreciated on the whole body maximal intensity projection (long arrow).

showed complete resolution of the pulmonary changes and complete metabolic response to therapy.

Discussion

Incidental PE was found in 0.32% of contrast-enhanced ¹⁸F-FDG PET/CT scans in one retrospective study [3]. Protocolling for ¹⁸F-FDG PET/CT depends on practicespecific preferences and patient contraindications such as renal impairment and prior contrast reaction. Many patients will undergo a non-contrast study which poses even greater challenge for diagnosing PE. Nonetheless, the importance of recognizing potential PE cannot be overstated given the high pre-test probability in the at-risk population of oncology patients and the potential for catastrophic outcomes in undiagnosed PE. In these patients there is a reliance on secondary signs of PE. In addition, where contrast is used it is typically acquired with contrast in an arterial phase and during free respiration, which is far from ideal when attempting to detect small and/or basal emboli. Therefore, even when contrast-enhanced ¹⁸F-FDG PET/CT is used, an understanding of the indirect signs of PE is invaluable.

The two most distinguishable signs of a PE on a noncontrast-enhanced ¹⁸F-FDG PET/CT scan are the "rim sign" which indicates a pulmonary infarction and abnormal cardiac uptake associated with RHS. Other signs include hypermetabolism and hypometabolic filling defects in the pulmonary artery, but these are less reliable. A pulmonary infarction manifests as an area of geographical coagulative necrosis in the subpleural region with islands of viable lung parenchyma and a reparative margin of granulation tissue with a well-defined edge consisting of palisading histiocytes and foamy macrophages [4]. The peripheral inflammation demonstrates variable FDG uptake resulting in the "rim sign." As pulmonary infarctions are absent in the majority of cases of PE, the absence of "rim sign" in no way reliably excludes the diagnosis [5]. Additionally, a centrally necrotic tumour can mimic the appearance of the "rim sign" and the degree of uptake similar to low-grade primary lung neoplasm such as adenocarcinoma. In our case, observing the pulmonary infarct on CT may have prompted search for PE via CTPA earlier; however, this requires astute interpretation and high index of suspicion.

The presence of alternative indirect signs for PE such as RHS in this case report can greatly increase diagnostic confidence. Under normal physiological circumstances, only the left ventricle will typically show FDG uptake. In the setting of PE, increased pulmonary arterial resistance and tachycardia contribute to increased metabolic demand, which can alter the distribution of FDG within the heart. Uptake within the right ventricular wall and both atria has been described [3,6]. It should be noted that RHS is not specific to PE and can also present due to underlying heart or lung disease.

In this case, the patient had moderate right atrial uptake and only very subtle right ventricular uptake. This is a different pattern to the case reported by Franceschi et al. [6] describing intense right atrial and ventricular uptake. In this case, the patient was asymptomatic at the time of the scan and subsequently deteriorated. This raises the possibility that right atrial uptake is an earlier sign of RHS than right ventricular uptake, although this would require further study to confirm. Indeed observing a new finding of RHS should prompt the interpreting physician to enquire to the clinical status of the patient, communication with the referring clinician to ascertain the need for urgent CTPA.

PE is a challenging diagnosis on non-contrast-enhanced ¹⁸F-FDG PET/CT. While many cases of PE will remain undetectable, awareness of indirect signs such as the "rim sign" and abnormal cardiac FDG uptake may prevent potentially catastrophic outcomes in at-risk oncology patients.

Disclosure Statement

Appropriate written informed consent was obtained for publication of this case report and accompanying images.

References

- 1. Noble S, and Pasi J. 2010. Epidemiology and pathophysiology of cancer-associated thrombosis. Br. J. Cancer 102(S1):S2–S9.
- Blom JW, Doggen CJM, Osanto S, et al. 2005. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722.
- Flavell RR, Behr SC, Brunsing RL, et al. 2014. The incidence of pulmonary embolism and associated FDG-PET findings in IV contrast-enhanced PET/CT. Acad. Radiol. 21:718–725.
- 4. Yousem SA. 2009. The surgical pathology of pulmonary infarcts: diagnostic confusion with granulomatous disease, vasculitis and neoplasia. Mod. Pathol. 22:679–685.
- Soussan M, Rust E, Pop G, et al. 2012. The rim sign: FDG-PET/CT pattern of pulmonary infarction. Insights Imaging 3 (6):629–633.
- Franceschi AM, Matthews R, Mankes S, et al. 2012. Four chamber FDG uptake in the heart: an indirect sign of pulmonary embolism. Clin. Nucl. Med. 37:687–691.